- Home
- IBTA vs ALT Comparison
IBTA vs ALT Comparison
Compare IBTA & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBTA | ALT |
|---|---|---|
| Founded | 2011 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 605.8M | 576.0M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | IBTA | ALT |
|---|---|---|
| Price | $21.46 | $5.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $37.38 | $16.33 |
| AVG Volume (30 Days) | 465.4K | ★ 3.5M |
| Earning Date | 11-12-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 395.09 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $352,243,000.00 | $20,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.91 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.40 | $2.90 |
| 52 Week High | $76.00 | $9.59 |
Technical Indicators
Market Signals| Indicator | IBTA | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 32.37 | 61.41 |
| Support Level | $22.19 | $5.03 |
| Resistance Level | $24.40 | $5.83 |
| Average True Range (ATR) | 0.88 | 0.38 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 2.56 | 47.00 |
Price Performance
Historical ComparisonAbout IBTA Ibotta Inc.
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.